Travere Therapeutics Competitors and Similar CompaniesClear all

Travere Therapeutics's competitors and similar companies include Genexine and Kamada Pharmaceuticals.
Travere Therapeutics
Travere Therapeutics
Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.
Genexine
Genexine
Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics.
Kamada Pharmaceuticals
Kamada Pharmaceuticals
Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications.
Founding Date
Founding Date
2011
Founding Date
1999
Founding Date
1990
Type
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
San Diego, US HQ
Dublin, IE
Locations
Seongnam-si, KR HQ
New York, US
Locations
Rehovot, IL HQ
Beit Kama, IL
Employees
Employees
46293% increase
Employees
983% decrease
Employees
3781% decrease
Valuation ($)
Valuation ($)
514.6 m
Valuation ($)
N/A
Valuation ($)
301.2 m

Financial

Revenue (est.)
Revenue (est.)
$145.2m (FY, 2023)
Revenue (est.)
₩16.1b (FY, 2022)
Revenue (est.)
$142.5m (FY, 2023)
Cost of goods
Cost of goods
$11.5m (FY, 2023)
Cost of goods
(₩2.1b) (FY, 2022)
Cost of goods
$61.7m (FY, 2023)
Gross profit
Gross profit
$133.8m (FY, 2023)
Gross profit
₩20.3b (FY, 2022)
Gross profit
$80.8m (FY, 2023)
Net income
Net income
($111.4m) (FY, 2023)
Net income
(₩57.1b) (FY, 2022)
Net income
$8.3m (FY, 2023)

Funding

Total funding raised
Total funding raised
$ 25m
Total funding raised
N/A
Total funding raised
$ 90m
For sources of this data, please see the company profile

View Company Profiles

Genexine
HQ
Seongnam-si, KR
Employees
98↓ 3% decrease

Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics.

View company
Kamada Pharmaceuticals
HQ
Rehovot, IL
Employees
378↓ 1% decrease

Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications.

View company